Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Body Surface Area and Baseline Blood Pressure Predict Subclinical Anthracycline Cardiotoxicity in Women Treated for Early Breast Cancer.

Kotwinski P, Smith G, Cooper J, Sanders J, Ma L, Teis A, Kotwinski D, Mythen M, Pennell DJ, Jones A, Montgomery H; Breast cancer Early disease: Toxicity from Therapy with Epirubicin Regimens–Cardiac Assessment and Risk Evaluation (BETTER-CARE) Study Investigators..

PLoS One. 2016 Dec 2;11(12):e0165262. doi: 10.1371/journal.pone.0165262. eCollection 2016.

2.

Long-term Toxicity of Cancer Treatment in Older Patients.

Shahrokni A, Wu AJ, Carter J, Lichtman SM.

Clin Geriatr Med. 2016 Feb;32(1):63-80. doi: 10.1016/j.cger.2015.08.005. Epub 2015 Oct 13. Review.

3.

Cardiac risk in the treatment of breast cancer: assessment and management.

Valachis A, Nilsson C.

Breast Cancer (Dove Med Press). 2015 Jan 16;7:21-35. doi: 10.2147/BCTT.S47227. eCollection 2015. Review.

4.

Cardiovascular toxicities from systemic breast cancer therapy.

Guo S, Wong S.

Front Oncol. 2014 Dec 4;4:346. doi: 10.3389/fonc.2014.00346. eCollection 2014. Review.

5.

Evaluation of lecithinized human recombinant super oxide dismutase as cardioprotectant in anthracycline-treated breast cancer patients.

Broeyer FJ, Osanto S, Suzuki J, de Jongh F, van Slooten H, Tanis BC, Bruning T, Bax JJ, Ritsema van Eck HJ, de Kam ML, Cohen AF, Mituzhima Y, Burggraaf J.

Br J Clin Pharmacol. 2014 Nov;78(5):950-60. doi: 10.1111/bcp.12429.

6.
7.

Helical tomotherapy for inoperable breast cancer: a new promising tool.

Chira C, Kirova YM, Liem X, Campana F, Peurien D, Amessis M, Fournier-Bidoz N, Pierga JY, Dendale R, Bey P, Fourquet A.

Biomed Res Int. 2013;2013:264306. doi: 10.1155/2013/264306. Epub 2013 Sep 2.

8.

Mitochondria death/survival signaling pathways in cardiotoxicity induced by anthracyclines and anticancer-targeted therapies.

Montaigne D, Hurt C, Neviere R.

Biochem Res Int. 2012;2012:951539. doi: 10.1155/2012/951539. Epub 2012 Mar 20.

9.

Cardiovascular complications of breast cancer therapy in older adults.

Shenoy C, Klem I, Crowley AL, Patel MR, Winchester MA, Owusu C, Kimmick GG.

Oncologist. 2011;16(8):1138-43. doi: 10.1634/theoncologist.2010-0348. Epub 2011 Jul 7. Review.

10.

Effect of Supplementation of Tanshinone IIA and Sodium Tanshinone IIA Sulfonate on the Anticancer Effect of Epirubicin: An In Vitro Study.

Chan SE, Lai HW, Su CC, Kuo SJ, Chien SY, Lin HY, Chen DR.

Evid Based Complement Alternat Med. 2011;2011:841564. doi: 10.1155/2011/841564. Epub 2011 May 24.

11.

Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.

Romero A, Martín M, Cheang MC, López García-Asenjo JA, Oliva B, He X, de la Hoya M, García Sáenz JÁ, Arroyo Fernández M, Díaz Rubio E, Perou CM, Caldés Llopis T.

Am J Pathol. 2011 Apr;178(4):1453-60. doi: 10.1016/j.ajpath.2010.12.042. Review.

12.

Cardiovascular effects in childhood cancer survivors treated with anthracyclines.

Franco VI, Henkel JM, Miller TL, Lipshultz SE.

Cardiol Res Pract. 2011 Feb 10;2011:134679. doi: 10.4061/2011/134679.

13.

Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials.

Al-Batran SE, Güntner M, Pauligk C, Scholz M, Chen R, Beiss B, Stopatschinskaja S, Lerbs W, Harbeck N, Jäger E.

Br J Cancer. 2010 Nov 9;103(10):1518-23. doi: 10.1038/sj.bjc.6605961. Epub 2010 Oct 26.

Supplemental Content

Support Center